上海医药集团(本溪)北方药业有限公司

Shanghai Pharmaceutical Group (Benxi) Northern Pharmaceutical Co., Ltd. (referred to as "SPG Northern Pharma") is a wholly-owned subsidiary of Shanghai Pharmaceuticals Holding Co., Ltd., a Fortune Global 500 company. It operates under the Shanghai Pharmaceutical Central Research Institute and was established in November 2014. The company covers an area of 73,000 square meters with a registered capital of 380 million RMB. The construction is divided into two phases: the first phase is the "Chemical Drug R&D Pilot and Industrialization Project," and the second phase is the "ADC Drug Pilot and Production Construction Project," with a total investment exceeding 1 billion RMB.

SPG Northern Pharma provides CMC services, professional testing services, and IND application support for chemical and biotechnology companies both domestically and internationally. Its offerings include chemical APIs, intermediates, oral formulations, chemical injections, and ADC preparations. The company is dedicated to the R&D, pilot testing, and scale-up of chemical and biological drugs, aiming to build an internationally aligned, domestically leading, and core-competitive MAH-based manufacturing base for innovative drugs and high-end formulations.

Honors and Certifications: The company has obtained CNAS certification and is recognized as a high-tech enterprise. It has been awarded honors such as the Liaoning Provincial Technological Innovation Center for Antitumor Drugs, Liaoning Provincial Chemical Drug Pilot Base, Public Technical Service Platform for Liposome and Microemulsion Formulations, Liaoning Provincial Engineering Laboratory for Liposome and Microemulsion Technology, and the leading unit of the Liaoning Provincial High-End Formulation Industry-University-Research Alliance.